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Abstract
Background: To date, there has been no comprehensive study on the association between atrial fibrillation (AF)
and multimorbidity. The present study investigated the epidemiology of AF and the association between
multimorbidity and the onset of AF. In addition, the correlation between multimorbidity and the use of
anticoagulants and the risk of cerebrovascular events considering multimorbidity was explored in AF patients.
Methods: Intego is a primary care registry network in Belgium. A case–control study was performed using Intego
data from a 10-year time interval (2002 to 2011). All patients aged 60 years and older in 2002 who had developed
new AF between 2002 and 2011 were selected, as well as a group of matched control patients. In addition, the
prescription of anticoagulants and incident cerebrovascular events were recorded in patients with AF.
Results: AF showed a prevalence of 5.3 % in 2002, and an upward trend was observed between 2002 and 2011. In
all, 1830 patients with AF and 6622 control patients were included. AF patients had significantly more comorbidities
(mCCI (modified Charlson Comorbidity Index) 5 ± 2 vs 4 ± 2, P < 0.001). In addition, 9.7 % of patients with AF
developed a cerebrovascular event (mean follow-up time of 2.7 ± 2.5 years). Both the under- and overuse of
anticoagulants was observed. Of the 49 % of patients with AF who were considered at high risk (CHADS2 ≥ 2), 50 %
received anticoagulants in the first six months after diagnosis, whereas 49 % of patients who were at low risk
(CHADS2 = 0) did not.
Conclusions: AF is highly prevalent in older primary care patients and is significantly associated with
multimorbidity. A discrepancy between the guidelines and clinical practice of anticoagulant use was observed. As
multimorbidity seems to play a role in this, further qualitative research to study the perception and motives of the
general practitioner is needed.
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Background
Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia. The prevalence of AF is known to
increase with age: more than three-quarters of patients
with AF are older than 65 years [1]. AF currently affects
more than 8.8 million adults in the European Union.
This number is expected to double within the next
50 years as the population ages rapidly [2]. Patients with
AF typically have multiple comorbidities and have a
higher risk of cerebrovascular events compared with that
of individuals without the condition [3]. As a result,
knowledge of the interactions between comorbidity and
AF, as well as good anticoagulation management are a
primary challenge both for medical and economic rea-
sons. General practitioners (GPs) play a key role in the
patient-centred care of older patients with AF and con-
comitant conditions.
Oral anticoagulation treatment for high stroke-risk pa-
tients with AF has been demonstrated to be effective in
reducing the risk of a stroke [4]. Stroke risk is assessed
using the CHADS2 and CHA2DS2-VASc scores, vali-
dated stratification schemes in which the presence of
certain comorbidities determines the need for anticoagu-
lation treatment [5, 6]. Because increasing age itself is an
important risk factor for a stroke, international guide-
lines recommend also using these scoring systems for
older patients with AF [7, 8].
Nevertheless, many reports suggest genuine underuse
of anticoagulants in elderly patients, even when correct-
ing for the increased risk of bleeding in this age group
[9, 10]. Increasing prevalence of multimorbidity in pri-
mary care complicates treatment [11]. To date, very few
studies have assessed the link between AF, multimorbid-
ity and stroke risk in older patients.
Therefore, this registry-based study investigated the
epidemiology of AF and the association between multi-
morbidity and the onset of AF. In addition, the correl-
ation between multimorbidity and the prescription of
anticoagulants and the risk of cerebrovascular events
considering multimorbidity over a 10-year time interval
was explored in AF patients. The central hypothesis was
that multimorbidity plays an important role in the aeti-
ology of AF and in the treatment and future risk of cere-
brovascular events for people who develop AF.
Methods
Study design
Data were obtained from Intego, a Flemish general
practice-based morbidity registration network at the
Department of General Practice of the University of
Leuven [12]. Ninety-seven general practitioners (GPs),
all using the medical software programme Medidoc
(Corilus NV, Aalter, Belgium), collaborated in the Intego
project. These 97 GPs work in 55 practices evenly spread
over Flanders, Belgium. GPs applied for inclusion in the
registry. Before acceptance of their data, registration per-
formance was audited using a number of algorithms that
compared their results with those of all other applicants.
Only the data of the practices with an optimal registra-
tion performance were included in the database. The se-
lection procedure has been described in detail previously
[12]. The Intego GPs prospectively and routinely regis-
tered all new diagnoses together with new drug prescrip-
tions, as well as laboratory test results and some
background information (including gender and year of
birth), using computer-generated keywords internally
linked to codes. Using specially framed extraction soft-
ware, new data were encrypted and collected from the
GPs’ personal computers and entered into a central
database. Registered data were continuously updated
and historically accumulated for each patient. New
diagnoses were classified according to a very detailed
thesaurus automatically linked to the International Clas-
sification of Primary Care (ICPC-2) and International
Statistical Classification of Diseases and Related Health
Problems 10th Revision (ICD-10). Drugs were classified
according to the WHO’s Anatomical Therapeutic Chem-
ical (ATC) classification system.
Intego started to collect data in 1994, but for the
present study, data over a 10-year time interval from
January 1st, 2002, to December 31st, 2011, were used.
Study population
In 2002, 20,301 patients registered in the Intego data-
base were aged 60 years and older and had at least had
one contact with their general practitioner. Of these,
1068 had already been diagnosed with AF before 2002
and were therefore excluded from our study. The inclu-
sion criterion for the cases was a reported first diagnosis
of AF between January 1st, 2002 and December 31st,
2011. In total 1830 patients were diagnosed with AF. All
participants were followed until the last contact date in
the Intego registry or until December 31st, 2011, which-
ever came first.
Each patient with AF was matched with 3 to 4 control
patients, bringing the number of controls up to 6622
[13]. These patients were still in the Intego database at
the moment of the AF diagnosis in the case, belonged to
the same age stratum in 2002 (i.e., 60–69, 70–79 or
≥80 years old), were of the same gender and originated
from the same GP practice but had not been diagnosed
with AF before or during the follow-up period.
Clinical characteristics
Outcome variables
The first outcome variable was the diagnosis of AF. The
date of diagnosis served as the baseline date for the case
and its matched controls. The association between AF
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and comorbidities was explored in the entire group of
cases and controls (n = 8452). A second outcome vari-
able was the diagnosis of a cerebrovascular event (i.e.,
transient ischaemic attack (TIA) (ICPC – code K89) or
cerebrovascular accident (ICPC – code K90)) in patients
with AF after baseline. The risk of cerebrovascular
events was calculated in the group of cases (n = 1830).
The internationally used definition of TIA changed in
2009, during our follow-up period. Whereas the tempor-
ary nature of neurologic symptoms (<24 h) were previ-
ously emphasized, a TIA is currently defined as a
transient episode of neurological dysfunction caused by
focal brain, spinal cord, or retinal ischaemia without
acute infarction [14]. It is unclear which of both defini-
tions the GPs used. Therefore, we here used ‘cerebrovas-
cular event’ for both TIA and CVA.
CHADS2 and CHA2DS2-VASc (congestive heart fail-
ure, hypertension, age ≥75 years, diabetes mellitus, prior
cerebrovascular event or thromboembolism, vascular
disease (myocardial infarction or peripheral arterial dis-
ease), age 65–74 years and female gender) scores at
baseline were calculated to determine the risk of a cere-
brovascular event in patients with AF [5, 6].
Comorbidity
The Charlson Comorbidity Index (CCI) includes 19
chronic diseases, which are weighted based on their as-
sociation with mortality [15]. The presence of these
chronic diseases was not assessed for this study, but the
history of chronic diseases is registered by the general
practitioner in the electronic health record. A one-time
registration before the baseline date was considered
positive for cases and controls. The following diagnoses
were included: diabetes mellitus; a history of myocardial
infarction; heart failure; a history of cerebrovascular
event; peripheral arterial illness; chronic pulmonary dis-
ease; a history of peptic ulcer; dementia; liver disease;
hemiplegia; a history of cancer; a history of leukaemia; a
history of lymphoma; and AIDS. Connective tissue dis-
ease could not be reliably assessed from the registry.
Furthermore, the differentiation between cancers with or
without metastasis, diabetes with or without end organ
failure, and mild or moderate to severe liver disease
could not be made. Consequently, all patients with any
cancer history were assigned the same score (=2), as
were all patients with diabetes (=1) and all patients with
liver disease (=1). Therefore, we used a modified CCI
(mCCI) in all further analyses [16].
The mCCI at the time of diagnosis of AF was calcu-
lated for each case and its controls. An mCCI was not
available for 87 patients with AF because no creatinine
levels were available in the database. In addition to the
mCCI, diagnoses of hypertension and valvular heart dis-
ease were extracted at baseline.
Pharmacotherapy
The prescription of cardiovascular medication (ATC-
coded) including beta-blockers, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers,
calcium antagonists, diuretics, digitalis and antiarrhyth-
mic drugs was extracted for every study participant at
baseline and six months after the diagnosis of AF.
The prescription of antithrombotic therapy was regis-
tered for cases in the first six months after the diagnosis
of AF (ATC-coded: heparin, acetylsalicylic acid, thienopyr-
idine, dipyridamol, vitamin K antagonists). Throughout
this paper we used the term ‘anticoagulants’ for both oral
anticoagulants (vitamin K antagonists) and subcutaneous
heparin treatment. When assessing whether patients were
receiving anticoagulation treatment after the diagnosis of
AF, we used a six-month time frame as there could be a
doctor-related delay in registering treatment changes.
Data analysis
Continuous data are presented as the mean and standard
deviation (SD). Categorical data are presented as num-
bers and frequencies. Comparisons between cases and
controls were performed using the independent samples
t-test or the χ2 test for categorical data.
The prevalence and incidence of AF for each year were
calculated in the yearly contact group. These included
all the Intego patients of 60 years and older who had
had at least one contact with their GP that year. Further
analyses were made using the data from patients in-
cluded in the case–control study.
The association between the presentation of novel AF
and comorbidity was explored in the entire study popu-
lation (n = 8452) by calculating odds ratios (ORs) with
the corresponding 95 % confidence intervals (CIs) using
bivariate and multivariable binary conditional logistic re-
gression analyses adjusting for cardiovascular medication
at the moment of diagnosis. Two different models were
used; one with the mCCI and one with the different co-
morbidities of the mCCI without the overall index.
These analyses were also performed in different age
strata to see whether the pattern of multimorbidity in
relation to AF changes between age groups.
The risk of cerebrovascular event after baseline in pa-
tients with AF (n = 1830) was calculated using a Cox
proportional hazards model and adjusted for age and
gender. Two different models were used: one with the
mCCI and CHADS2 or CHA2DS2-VASc score and one
with the different comorbidities without the overall
index.
The association between the prescription of anticoagu-
lants in the first six months after baseline and multimor-
bidity was investigated in patients with AF (n = 1830)
using bivariate and multivariable binary logistic regression
analyses adjusting for age, gender and cardiovascular
Vanbeselaere et al. BMC Cardiovascular Disorders  (2016) 16:61 Page 3 of 12
medication prescribed in the six months after baseline.
Two models were used: one with the mCCI and CHADS2
or CHA2DS2-VASc score and one with the different co-
morbidities without the overall index.
Subsequently, in patients with AF who developed a
cerebrovascular event, individual patient profiles were
investigated to explore further the relationship between
the prescription of anticoagulation and the incidence of
cerebrovascular events. For those who had received oral
anticoagulation treatment (vitamin K antagonists), the
last INR values before the cerebrovascular event were
checked to see whether they were within a therapeutic
range (INR 2–3.5) (cross section method for time-in-
therapeutic range). Patients who had received a first
diagnosis of AF at the same time as when they had had
a cerebrovascular event were excluded from certain ana-
lyses because there had been no time to administer anti-
coagulants before the event.
To avoid co-linearity, the correlation coefficients
between all covariates were calculated. In the case of co-
linearity (Pearson’s r >0.80), only one of the two covariates
was considered in the multivariable model. When clinic-
ally relevant, interaction was assessed between the vari-
ables used in the analyses. If the interaction term was
statistically significant (P <0.05), separate models were run
to assess the direction of association in different strata.
Statistical analyses were performed using SPSS 22.0
(SPSS Inc., Chicago, IL, USA).
Results
Epidemiology
Figure 1 shows the yearly prevalence of AF in the Intego
database in patients aged 60 years or older from 2002 to
2011. An upward trend was observed with an overall
prevalence of 5.3 % in 2002 compared with 6.4 % in
2011. The yearly incidence rate of AF is also shown in
Fig. 1. The overall incidence rate rose slightly from 6.4/
1000 patient-years in 2002 to 8.3/1000 patient-years in
2011. This upward trend was not present in the youn-
gest patient group. AF incidence was highest in the old-
est group of patients.
Our cohort included 8452 patients, of whom 1830 pa-
tients were diagnosed with AF between 2002 and 2011.
The mean age was 77 years, and 49 % of our patients
were men, as shown in Table 1.
Comorbidity
Cases differed significantly from controls for several pa-
rameters, such as the prescription of cardiovascular
medication and the presence of comorbidity (Table 1).
More specifically, patients with AF presented more often
with a history of myocardial infarction, heart failure, per-
ipheral vascular disease, a history of cerebrovascular
events, diabetes, renal disease, hypertension and valvular
heart disease. A total of 92 % of patients with AF had an
mCCI of ≥3 versus 90 % of the controls (P = 0.004).
The mCCI was independently associated with a higher
risk for AF (Table 2). In the model without the overall
index, a history of myocardial infarction, heart failure,
cerebrovascular event, renal disease and valvular heart
disease were independently associated with AF. Hyper-
tension was not independently associated, but antihyper-
tensive treatment with β blockers, calcium channel
blockers and ACE-inhibitors was associated with a
higher AF risk.
The analyses were repeated with patients split into
three age strata (Table 3). A history of heart failure and
valvular heart disease were independently associated
with AF in all age strata. Patients aged 60–79 years with
AF were prescribed more β blockers than the controls.
In patients aged 80 years and older, a strong and inde-
pendent association was observed between AF and ACE-
inhibitor prescription, diabetes, renal disease, a history
of tumours and hypertension that was not observed in
younger patients. However, the presence of diabetes and
a history of tumours were negatively associated with AF
diagnosis.
Cerebrovascular event
A cerebrovascular event was diagnosed in 178 of the
1830 AF patients (9.7 %) during the 10-year time period
(mean follow-up 2.7 ± 2.5 years). In total, 46 events
(26 %) occurred on the same day as the incident AF,
leaving 132 events occurring after the diagnosis of AF.
In the first six months after baseline, 78 patients (44 %)
developed a cerebrovascular event.
Fig. 1 Prevalence and incidence of atrial fibrillation in the Intego database in patients of 60 years and older
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In both the bivariate and the multivariable analyses, age
was associated with an incident cerebrovascular event in
patients with AF (HR 1.05 (95 % CI 1.03–1.07), per year
increase) (Table 4). Both CHADS2 and CHA2DS2-VASc
scores were strongly associated with a cerebrovascular
event (HR 1.5 (95 % CI 1.3–1.7) and HR 1.4 (95 % CI 1.2–
1.6), per point increase, respectively). Patients with AF
who had had a cerebrovascular event in the past were at a
much greater risk of a recurrent ischaemic cerebrovascu-
lar event (HR 5.2 (95 % CI 3.8–7.2)). An independent cor-
relation was also found between renal disease at baseline
and future risk of cerebrovascular events (HR 1.3 (95 % CI
1.1–1.6)).
Anticoagulation treatment
Determinants for receiving anticoagulants within the first
six months after baseline are shown in Table 5. Overall,
49 % (n = 895) of patients with AF in our study received
anticoagulants. In total, 53 % of men with AF were
prescribed anticoagulants, compared with 45 % of female
patients with AF. When split into age groups, 49 % of pa-
tients aged 60–69 years (n = 140), 52 % of patients aged
70–79 years (n = 425) and 45 % of patients aged 80 years
and older (n = 330) were prescribed anticoagulants.
Table 6 describes the prescription of anticoagulants ac-
cording to the CHADS2 and CHA2DS2-VASc score. On
the one hand, an overuse of anticoagulants was seen in pa-
tients with a low risk of cerebrovascular events (51 % of
patients with a CHADS2 score of 0 were prescribed antico-
agulants), and on the other hand an underuse of anticoa-
gulants was seen in patients with a high risk of
cerebrovascular events (50 % of patients with a CHADS2
score ≥2 were not prescribed anticoagulants). Overall, there
was no significant association between the CHADS2 (P =
0.079) or CHA2DS2-VASc score (P = 0.086) and receiving
anticoagulants after baseline.
Table 1 Baseline characteristics of patients with newly developed atrial fibrillation in the Intego database (2002–2011)a
Atrial fibrillation Control P value*
(n = 1830) (n = 6622)
Age (years), mean ± SD 77.5 ± 7.3 77.0 ± 7.2 0.006
Men, n (%) 900 (49.2) 3253 (49.1) 0.97
Cardiovascular medication before the diagnosis of atrial fibrillation, n (%) 1005 (54.9) 2523 (38.1) <0.001
Diuretic, n (%) 495 (27.0) 1198 (18.1) <0.001
β blocker, n (%) 603 (33.0) 1357 (20.5) <0.001
Calcium channel blocker, n (%) 303 (16.6) 674 (10.2) <0.001
ACE-inhibitor, n (%) 340 (18.6) 756 (11.4) <0.001
ARB, n (%) 172 (9.4) 440 (6.6) <0.001
Comorbidity
Charlson Comorbidity Index, mean ± SD 5 ± 2 4 ± 2 <0.001
Myocardial infarction, n (%) 235 (12.8) 513 (7.7) <0.001
Heart failure, n (%) 214 (11.7) 260 (3.9) <0.001
Peripheral vascular disease, n (%) 149 (8.1) 400 (6.0) 0.001
Cerebrovascular event, n (%) 259 (14.2) 633 (9.6) <0.001
Dementia, n (%) 62 (3.4) 242 (3.7) 0.59
Chronic pulmonary disease, n (%) 47 (2.6) 175 (2.6) 0.86
History of peptic ulcers, n (%) 150 (8.2) 472 (7.1) 0.12
Liver disease, n (%) 57 (3.1) 184 (2.8) 0.44
Diabetes, n (%) 319 (17.4) 884 (13.3) <0.001
Hemiplegia, n (%) 30 (1.6) 71 (1.1) 0.048
Renal disease, n (%) 208 (11.9) 480 (8.1) <0.001
History of tumours, n (%) 237 (13.0) 922 (13.9) 0.28
Leukaemia, n (%) 5 (0.3) 24 (0.4) 0.56
Lymphoma, n (%) 7 (0.4) 33 (0.5) 0.52
Hypertension, n (%) 780 (42.6) 2213 (33.4) <0.001
Valve disease, n (%) 181 (9.9) 235 (3.5) <0.001
a, the date of diagnosis of atrial fibrillation served as the baseline date for the case and its matched controls; *, independent samples t-test or Chi2 test
SD standard deviation, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
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Of the 132 patients who developed a cerebrovascular
event during the follow-up period, 34 (26 %) were taking
anticoagulation therapy at the time of their event. Of
these, 15 were within a therapeutic INR range (2–3.5) at
the time of the last blood test before the event, 13 were
controlled suboptimally (INR <2), whereas 3 had re-
ceived more than optimal anticoagulation treatment
(INR >3.5). For 3 patients receiving anticoagulants after
the diagnosis of AF, no INR values were available. At the
time of their cerebrovascular event, 98 patients were not
receiving anticoagulants. Of these, 14 (14 %) were pre-
scribed anticoagulants after the event.
Discussion
This study showed AF was highly prevalent in older pri-
mary care patients and was significantly associated with
multimorbidity. Multimorbidity was positively associated
with both AF development and cerebrovascular event risk
in patients with AF. A discrepancy between guidelines and
clinical practice in anticoagulation treatment was observed.
There was both under- and overuse of anticoagulants in pa-
tients with AF, possibly due to the multimorbidity of these
patients, complicating treatment.
Epidemiology
The prevalence of AF in our study population is com-
parable to the results of the Dutch Rotterdam Study, a
population-based prospective cohort study between
1990 and 2000 in patients aged 55 years and older [1].
They calculated an overall AF prevalence of 5.5 %,
whereas our overall prevalence was 5.3 % in 2002. The
overall incidence in the Rotterdam population was 9.9/
1000 patient-years, which was higher than the incidence
in our population. Both studies found a steep increase in
both prevalence and incidence with age.
An upward trend was observed in AF prevalence be-
tween 2001 and 2011. A study on the Global Burden of
Disease 2010 data confirms this modest upward trend
Table 2 Association between comorbidity and the development of atrial fibrillation (binary conditional logistic regression analysis, n= 8452)
Bivariate P value Multivariable P value
OR (95 % CI) OR (95 % CI)
Cardiovascular medicationa
Diuretic 1.7 (1.5–1.9) <0.001 1.1 (0.94–1.3) 0.24
β blocker 2.0 (1.8–2.2) <0.001 1.6 (1.4–1.8) <0.001
Calcium channel blocker 1.8 (1.5–2.0) <0.001 1.3 (1.1–1.5) 0.003
ACE-inhibitor 1.8 (1.6–2.1) <0.001 1.3 (1.1–1.5) 0.008
ARB 1.5 (1.2–1.8) <0.001 1.1 (0.85–1.3) 0.63
Comorbiditya
Charlson Comorbidity Index (per point increase) 1.12 (1.08–1.16) <0.001 1.09 (1.05–1.14)b <0.001
Myocardial infarction 1.8 (1.5–2.1) <0.001 1.3 (1.0–1.5) 0.021
Heart failure 3.3 (2.7–4.0) <0.001 2.5 (2.0–3.1) <0.001
Peripheral vascular disease 1.4 (1.1–1.7) 0.001 1.0 (0.82–1.3) 0.89
Cerebrovascular event 1.6 (1.3–1.8) <0.001 1.3 (1.1–1.6) 0.003
Dementia 0.89 (0.66–1.2) 0.43 0.86 (0.62–1.2) 0.37
Chronic pulmonary disease 1.0 (0.71–1.4) 0.99 0.94 (0.66–1.3) 0.72
History of peptic ulcers 1.2 (0.96–1.4) 0.12 1.0 (0.82–1.3) 0.92
Liver disease 1.1 (0.83–1.5) 0.47 0.99 (0.72–1.4) 0.96
Diabetes 1.4 (1.2–1.6) <0.001 1.1 (0.89–1.2) 0.58
Hemiplegia 1.5 (0.98–2.3) 0.058 1.1 (0.71–1.8) 0.61
Renal disease 1.5 (1.3–1.8) <0.001 1.4 (1.1–1.7) 0.001
History of tumours 0.92 (0.79–1.1) 0.31 0.86 (0.73–1.02) 0.086
Leukaemia 0.77 (0.29–2.0) 0.59 0.65 (0.22–1.9) 0.44
Lymphoma 0.75 (0.33–1.7) 0.49 0.85 (0.36–2.0) 0.72
Hypertension 1.5 (1.4–1.7) <0.001 1.1 (0.97–1.3) 0.15
Valve disease 3.1 (2.5–3.8) <0.001 2.5 (2.0–3.1) <0.001
aAll variables were recorded at baseline (= date of the diagnosis of atrial fibrillation for the case and its matched controls); b, Adjusted for diuretics intake, β blocker
intake, calcium channel inhibitor intake, ACE inhibitor intake, ARB intake, arterial hypertension and valve disease. OR odds ratio, CI confidence interval, ACE angiotensin-
converting enzyme, ARB angiotensin receptor blocker
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within the same time frame [17]. Several papers predict
a more dramatic escalation in AF burden in the coming
decades, both from a health care and whole-societal per-
spective [2, 18, 19].
Comorbidity
The results of our study exceed previous findings of the
high comorbidity index in patients with AF. The
National Health and Wellness Survey data [3] from 2009
showed 80 % of American patients with AF had a CCI of
0–2, and 21 % had scores ≥ 3 compared with 8 and 92 %,
respectively in our population. However, with a mean
age of 65 years, their population was younger than our
study population, which might explain the higher burden
of comorbidities in our study. Moreover, their study was
based on self-reports and thus possibly under-reported
data from an internet-based survey, which might have
excluded less computer-literate individuals. However,
findings of both studies were comparable with regards
to stroke-risk estimation with CHADS2 scores.
The current study found hypertension treatment, heart
failure, myocardial infarction, valvular heart disease and
renal disease to be independently associated with an in-
creased risk of new-onset AF, in line with very recent
statistical updates of AHA [20]. The relation between
AF and comorbidity existed even in the oldest patients.
The health burden carried by patients often extends far
beyond AF and specifically does so in older persons.
Cerebrovascular event
Almost 10 % of the patients with AF developed a cere-
brovascular event during the 10-year time interval, em-
phasizing the importance of the thrombo-embolic risk.
Although a history of cerebrovascular events before the
diagnosis of AF did not significantly alter anticoagula-
tion frequency, it was identified as a major risk factor for
Table 3 Association of comorbidity and the development of atrial fibrillation within different age strata (binary conditional logistic
regression analysis, n = 8452)
60–69 years (2002) 70–79 years (2002) ≥80 years (2002)
Bivariate Multivariable Bivariate Multivariable Bivariate Multivariable
Cardiovascular medicationa
Diuretic 1.6 (1.3–2.0)* 1.1 (0.82–1.4) 2.0 (1.7–2.4)* 1.3 (1.0–1.6)$ 1.2 (0.86–1.6) 0.77 (0.54–1.1)
β blocker 2.2 (1.8–2.7)* 1.8 (1.5–2.3)* 2.0 (1.7–2.4)* 1.6 (1.3–1.9)* 1.4 (1.0–1.9)$ 1.2 (0.80–1.7)
Calcium channel blocker 1.7 (1.3–2.2)* 1.2 (0.87–1.5) 2.1 (1.7–2.6)* 1.6 (1.3–2.0)* 1.1 (0.76–1.6) 0.89 (0.58–1.4)
ACE-inhibitor 1.7 (1.3–2.1)* 1.1 (0.86–1.5) 1.8 (1.5–2.3)* 1.2 (0.91–1.5) 2.1 (1.5–2.9)* 1.7 (1.1–2.6)$
ARB 1.8 (1.4–2.4)* 1.2 (0.89–1.7) 1.5 (1.1–1.9)$ 0.89 (0.64–1.2) 0.82 (0.45–1.5) 0.81 (0.42–1.6)
Comorbiditya
Charlson Comorbidity Index (per point increase) 1.2 (1.1–1.3)* 1.1 (1.0–1.2)μ,$ 1.1 (1.1–1.2)* 1.1 (1.0–1.2)μ,* 1.0 (0.94–1.1) 1.0 (0.93–1.1)μ
Myocardial infarction 2.2 (1.6–2.9)* 1.4 (0.97–1.9)£ 1.7 (1.3–2.1)* 1.2 (0.89–1.6) 1.6 (1.1–2.3)$ 1.3 (0.89–2.0)
Heart failure 4.4 (2.8–7.0)* 3.0 (1.8–5.0)* 3.6 (2.7–4.8)* 2.8 (2.0–3.9)* 2.4 (1.8–3.4)* 2.2 (1.5–3.2)*
Peripheral vascular disease 1.6 (1.1–2.3)$ 1.2 (0.79–1.8) 1.5 (1.1–2.0)$ 0.93 (0.68–1.3) 0.99 (0.62–1.6) 0.83 (0.49–1.4)
Cerebrovascular event 2.1 (1.6–2.9)* 1.7 (1.2–2.4)* 1.7 (1.4–2.2)* 1.5 (1.2–1.9)$ 0.98 (0.72–1.4) 0.84 (0.59–1.2)
Dementia 1.0 (0.33–3.0) 1.7 (0.51–5.3) 0.91 (0.60–1.4) 0.90 (0.56–1.4) 0.85 (0.55–1.3) 0.74 (0.45–1.2)
Chronic pulmonary disease 1.3 (0.75–2.4) 1.4 (0.77–2.6) 0.94 (0.57–1.6) 0.84 (0.50–1.4) 0.76 (0.37–1.6) 0.74 (0.34–1.6)
History of peptic ulcers 1.1 (0.75–1.5) 0.85 (0.58–1.2) 1.3 (0.97–1.7)£ 1.1 (0.78–1.4) 1.1 (0.71–1.7) 1.1 (0.71–1.8)
Liver disease 1.7 (1.1–2.6)$ 1.4 (0.87–2.2) 0.88 (0.55–1.4) 0.83 (0.50–1.3) 0.54 (0.20–1.5) 0.48 (0.17–1.4)
Diabetes 1.8 (1.4–2.3)* 1.3 (0.98–1.7)£ 1.4 (1.2–1.7)* 1.1 (0.83–1.3) 0.72 (0.49–1.1) 0.60 (0.39–0.92)$
Hemiplegia 1.6 (0.66–3.8) 0.87 (0.31–2.5) 1.5 (0.78–2.7) 1.1 (0.53–2.1) 1.6 (0.69–3.5) 1.8 (0.77–4.4)
Renal disease 1.6 (1.0–2.5)$ 1.1 (0.69–1.9) 1.6 (1.2–2.1)* 1.4 (1.0–1.8)$ 1.4 (1.1–1.9)$ 1.5 (1.1–2.1)$
History of tumours 0.92 (0.70–1.2) 0.83 (0.61–1.1) 1.1 (0.85–1.3) 1.0 (0.81–1.3) 0.63 (0.43–0.92)$ 0.60 (0.40–0.91)$
Leukaemia 0.61 (0.07–5.1) NA 0.85 (0.24–3.0) 0.87 (0.23–3.3) 0.72 (0.08–6.2) 0.97 (0.10–9.0)
Lymphoma 1.2 (0.25–6.1) 2.3 (0.36–15) 0.49 (0.14–1.7) 0.52 (0.15–1.8) 1.2 (0.24–5.9) 0.84 (0.14–4.9)
Hypertension 1.5 (1.2–1.8)* 1.0 (0.82–1.3) 1.6 (1.3–1.8)* 1.1 (0.91–1.3) 1.4 (1.1–1.8)$ 1.4 (1.0–1.8)$
Valve disease 3.1 (2.0–4.7)* 2.4 (1.5–3.9)* 2.9 (2.2–3.9)* 2.2 (1.6–3.0)* 3.7 (2.4–5.8)* 3.3 (2.1–5.3)*
aAll variables were recorded at baseline (= date of the diagnosis of atrial fibrillation for the case and its matched controls); *, P < 0.001; $, P < 0.05; £, P < 0.10;
μ, adjusted for diuretics intake, β blocker intake, calcium channel inhibitor intake, ACE inhibitor intake, ARB intake, arterial hypertension and valve disease
OR odds ratio, CI confidence interval, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
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a recurrent event. This is similar to the results of a sys-
tematic review published by, ‘The Stroke Risk in
Atrial Fibrillation Working Group’ [21]. A prior
stroke proved to be the most powerful risk factor and
reliably confers a high stroke risk in their study. Both
CHADS2 and CHA2DS2-VASc scores were strongly
associated with the risk of cerebrovascular events in
our patients with AF. The use of these scores is
mandatory in daily primary care practice. It might
also be important to be extra careful with patients
with AF and concomitant kidney problems, as our
study observed a high cerebrovascular event risk in
persons with renal disease.
Of the patients with AF who developed a cerebrovas-
cular event in our study, 26 % did so at the time of first
diagnosis of AF. Although it is possible that they devel-
oped an event immediately after the start of their heart
rhythm disorder, there might also be a doctor-related
delay in diagnosing heart rhythm problems in primary
care patients.
Anticoagulation treatment
Several studies have reported the underuse of anticoagu-
lants in older patients and increasing age has been re-
ported as a barrier to starting anticoagulants [1, 9, 10].
However, the current study showed that age, when cor-
rected for comorbidity, was not a significant determinant
of (not) receiving anticoagulants. This finding is in line
with the guidelines, which state that even for the very
elderly, the same risk-benefit analysis should be made to
determine the need for anticoagulants [7, 8, 22, 23].
A literature review has identified both patient- and
physician-related barriers to anticoagulation prescrip-
tion [24]. We observed both overtreatment in low
stroke-risk patients with AF and undertreatment in
patients at high stroke risk when compared with the
guidelines. CHADS2 and CHA2DS2-VASc scores were
not significantly associated with anticoagulation pre-
scription in our study. Of the patients at low risk for
a stroke more than 50 % received anticoagulants. The
same trend can be observed in other studies, such as
Table 4 Risk of a cerebrovascular event in patients with atrial fibrillation considering comorbidity (Cox regression analysis, n = 1830)
Bivariate P value Multivariable P value
HR (95 % CI) HR 95 % CI
Age (years)a 1.06 (1.03–1.08) <0.001 1.05 (1.03–1.07) <0.001
Men 0.82 (0.61–1.1) 0.19 1.1 (0.76–1.5) 0.74
Comorbiditya
CHADS2 score
b 1.7 (1.5–1.9) <0.001 1.5 (1.3–1.7)c <0.001
CHA2DS2-VASc score
b 1.5 (1.3–1.6) <0.001 1.4 (1.2–1.6)d <0.001
Charlson Comorbidity Indexb 1.3 (1.2–1.4) <0.001 1.1 (0.97–1.2)c 0.14
Myocardial infarction 0.87 (0.54–1.4) 0.55 0.64 (0.39–1.0) 0.075
Heart failure 1.2 (0.75–1.8) 0.48 0.90 (0.57–1.4) 0.65
Peripheral vascular disease 1.9 (1.2–2.9) 0.006 1.5 (0.94–2.3) 0.093
Cerebrovascular event 5.6 (4.1–7.5) <0.001 5.2 (3.8–7.2) <0.001
Dementia 1.9 (0.93–3.8) 0.081 1.0 (0.48–2.1) 0.99
Chronic pulmonary disease 0.24 (0.034–1.7) 0.16 0.17 (0.024–1.2) 0.081
History of peptic ulcers 0.83 (0.46–1.5) 0.53 0.74 (0.41–1.3) 0.32
Liver disease 1.6 (0.82–3.1) 0.17 1.4 (0.69–2.8) 0.36
Diabetes 1.2 (0.80–1.7) 0.44 1.3 (0.87–1.9) 0.21
Hemiplegia 1.6 (0.61–4.4) 0.32 0.63 (0.23–1.8) 0.38
Renal disease 1.4 (1.2–1.7) <0.001 1.3 (1.1–1.6) 0.006
History of tumours 1.3 (0.90–2.0) 0.15 1.1 (0.74–1.7) 0.59
Leukaemia 3.3 (0.46–24) 0.23 3.1 (0.42–23) 0.27
Lymphoma 0.049 (0.0–2923) 0.59 0.0 (0.0–5.0 × e261) 0.96
Hypertension 0.98 (0.73–1.3) 0.92 0.94 (0.69–1.3) 0.69
Valve disease 0.89 (0.53–1.5) 0.65 0.81 (0.48–1.4) 0.44
aAll variables were recorded at baseline (= date of the diagnosis of atrial fibrillation for the case); b, per point increase; c, adjusted for age, gender, valve disease
and CHADS2 or Charlson Comorbidity index;
d, adjusted for age, valve disease and Charlson Comorbidity index (the correlation coefficient between the CHADS2
and the CHA2DS2-VASc score was 0.91)
HR hazard ratio, CI confidence interval, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
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the ORBIT-AF study [25]. Although it is possible that
these patients may have received anticoagulants for
conditions other than AF, it is unlikely that these
conditions alone would account for the relatively high
anticoagulation rates. GPs may be prescribing antico-
agulants for these patients simply because they have
AF, regardless of their low stroke risk. On the contrary,
only 50 % of the individuals with a high risk of stroke
(CHADS2 ≥ 2) were receiving anticoagulants. This is com-
parable to findings in other studies [3, 26]. It is possible
that GPs are not aware of how infrequently they prescribe
anticoagulants. Therefore, it is important that quality of
Table 5 Determinants of receiving anticoagulants in the 6 months after the diagnosis of atrial fibrillation (binary logistic regression
analysis, n = 1830)
Bivariate P value Multivariable P value
OR (95 % CI) OR 95 % CI
Age (years)a 0.98 (0.96–0.99) <0.001 1.00 (0.98–1.01) 0.74
Men 1.3 (1.1–1.6) 0.002 1.5 (1.2–1.8) 0.001
Medicationa
Digitalis 1.9 (1.4–2.5) <0.001 2.0 (1.4–2.7) <0.001
Antiarrhythmic drug 2.4 (1.9–3.0) <0.001 2.0 (1.6–2.5) <0.001
Antihypertensive medication
Diuretic 2.5 (2.1–3.0) <0.001 1.5 (1.2–1.9) 0.001
β blocker 3.1 (2.5–3.7) <0.001 2.4 (1.9–2.9) <0.001
Calcium channel blocker 2.2 (1.7–2.8) <0.001 1.6 (1.2–2.1) 0.003
ACE-inhibitor 2.1 (1.7–2.6) <0.001 1.5 (1.1–1.9) 0.003
ARB 3.0 (2.2–4.3) <0.001 2.3 (1.6–3.4) <0.001
Comorbiditya
CHADS2 score
b 1.0 (0.94–1.1) 0.64 1.1 (0.99–1.3)c 0.079
CHA2DS2-VASc score
b 0.98 (0.92–1.0) 0.57 1.1 (0.99–1.3)d 0.086
Charlson Comorbidity Indexb 0.91 (0.86–0.96) <0.001 0.90 (0.83–0.97)c 0.009
Myocardial infarction 1.0 (0.79–1.4) 0.77 0.84 (0.61–1.2) 0.29
Heart failure 0.99 (0.74–1.3) 0.92 1.0 (0.72–1.4) 0.92
Peripheral vascular disease 1.2 (0.86–1.7) 0.30 1.2 (0.80–1.7) 0.41
Cerebrovascular event 1.1 (0.82–1.4) 0.66 1.2 (0.86–1.6) 0.32
Dementia 0.19 (0.097–0.38) <0.001 0.26 (0.12–0.56) <0.001
Chronic pulmonary disease 1.9 (1.0–3.4) 0.041 1.9 (0.97–3.7) 0.062
History of peptic ulcers 0.74 (0.53–1.0) 0.078 0.66 (0.45–0.96) 0.031
Liver disease 0.94 (0.55–1.6) 0.81 0.94 (0.51–1.7) 0.85
Diabetes 1.2 (0.96–1.6) 0.11 1.1 (0.85–1.5) 0.40
Hemiplegia 0.60 (0.28–1.3) 0.18 0.77 (0.33–1.8) 0.56
Renal disease 0.84 (0.73–0.97) 0.021 0.88 (0.74–1.0) 0.14
History of tumours 0.70 (0.53–0.93) 0.013 0.67 (0.49–0.92) 0.012
Leukaemia 0.26 (0.029–2.3) 0.23 0.36 (0.038–3.5) 0.38
Lymphoma 1.4 (0.31–6.2) 0.66 0.93 (0.19–4.5) 0.92
Hypertension 1.3 (1.0–1.5) 0.016 1.0 (0.82–1.3) 0.86
Valve disease 1.2 (0.88–1.6) 0.24 1.2 (0.87–1.8) 0.24
Cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation 1.6 (1.0–2.6) 0.042 1.8 (1.0–3.1) 0.039
a All variables were recorded at baseline (= date of the diagnosis of atrial fibrillation for the case), except cerebrovascular event in the first 6 months after the
diagnosis of atrial fibrillation; b, per point increase; c, adjusted for age, gender, digitalis intake, antiarrhythmic drug intake, diuretic intake, β blocker intake, calcium
channel blocker intake, ACE inhibitor intake, ARB intake, valve disease, cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation and CHADS2
or Charlson Comorbidity index; d, adjusted for age, digitalis intake, antiarrhythmic drug intake, diuretic intake, β blocker intake, calcium channel blocker intake,
ACE inhibitor intake, ARB intake, valve disease, cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation and Charlson Comorbidity index (the
correlation coefficient between the CHADS2 and the CHA2DS2-VASc score was 0.91)
OR odds ratio, CI confidence interval, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
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care audits can easily be performed with their medical
software programme.
Another reason for under-anticoagulation could be the
bleeding risk of a patient with AF, as perceived by the
GP. Patients with a history of peptic ulcers or a history
of tumours received less anticoagulants, probably due to
a high perceived bleeding risk. Patients suffering from
dementia also received less anticoagulants. Fear of poor
compliance and risk of falls might play a role in this.
The perceived thrombo-embolic risk of patients with
AF could be a physician-related barrier to anticoagula-
tion prescription. For example, male patients with AF in
our Intego population more frequently received antico-
agulants than women did. This finding is consistent with
results from other studies [10]. Gender inequalities have
been observed in the use of therapies in other areas of
cardiovascular medicine and have been attributed to a
possible lower perceived risk of cardiovascular disease in
women compared with men, leading to an underrecord-
ing of risk factors and lower rates of prophylactic treat-
ment in women [27]. However, the female gender is a
component of the CHA2DS2-VASc score because epide-
miologic data have shown that women have an increased
thrombo-embolic risk compared to men [6].
Much research on anticoagulation in patients with AF
has already been done and clinically useful guidelines
have been developed [4, 7–10, 22, 24–26]. Thorough
knowledge of the guidelines by the GPs is important to
make evidence-based decisions. However, our study
illustrates that there is still a discrepancy between the
guidelines and clinical practice for stroke prevention in
older patients with AF. It is important to clarify further
the barriers that GPs experience when treating older
patients with AF. As multimorbidity seems to play a role
in the therapeutic decision-making process and in the
risk of a stroke, it is important to understand fully its
impact. Therefore, more qualitative research, such as
focus group research or semi-structured interviews,
needs to be performed to further investigate attitudes of
GPs in prescribing anticoagulants for patients with AF
and multimorbidity. Care plans should be designed and
implemented according to the individual medical history,
risk factors and needs of each patient. Primary care physi-
cians are probably in the best position to take the key role
in managing the care of our older patients.
Strengths and limitations
A strong point of this study is the inclusion of a large
primary care population, representative of the popula-
tion in Flanders. In Belgium, the general practitioner is
the central actor in the health care system. More than
95 % of people aged 60 and over have a regular general
practitioner, and >90 % have at least one contact with
their general practitioner every year [28]. The database
contains all introduced diagnoses and most of the rele-
vant clinical parameters. Due to the retrospective design,
there was a 10-year follow-up of the clinical and
biological parameters. Data analyses with longitudinal
models incorporated between-subject (i.e., case – control)
and within-subject analyses with the inclusion of
timely changes in diagnoses and drug prescriptions.
Therefore, we were able to perform the first compre-
hensive study about AF and multimorbidity in a pri-
mary care setting.
The limitations were the lack of mortality data and the
lack of a creatinine value for <5 % of the included patients
with AF. Due to database limitations, data to calculate
HASBLED-scores, estimating the bleeding risk of a patient
with AF, were not available. Recently, anticoagulation-
therapy options have changed due to the introduction of
the NOACs (i.e., factor Xa and thrombin inhibitors).
These were not taken into account because the drugs were
not yet available in Belgium before 2012.
Conclusion
With a prevalence of 6.4 % in patients aged 60 years and
older in 2011, AF is a very frequent condition in elderly
primary care patients and a major risk factor for cere-
brovascular events. Due to ageing of the population, AF
prevalence is expected to rise in the coming decades,
making preventative strategies to reduce the risk of AF
within comprehensive health management programmes
Table 6 Prescription of anticoagulants according to the CHADS2 and CHA2DS2-VASc score in the first six months after the diagnosis
of atrial fibrillation (n = 1830)
CHADS2 score
0 (n = 285, 15.5 %) 1 (n = 654, 36 %) ≥2 (n = 891, 48.5 %)
Anticoagulants, n (%) 146 (51) 306 (47) 443 (50)
No anticoagulants, n (%) 139 (49) 348 (53) 448 (50)
CHA2DS2-VASc score
0 (n = 19, 1 %) 1 (n = 157, 9 %) ≥2 (n = 1654, 90 %)
Anticoagulants, n (%) 11 (58) 81 (52) 803 (49)
No anticoagulants, n (%) 8 (42) 76 (48) 851 (51)
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increasingly important. Our study confirms the very high
burden of comorbidities in patients with AF. These
conditions are predictors of both AF development and
cerebrovascular event risk in patients with AF and
should thus be considered when making decisions about
anticoagulation treatment. There is both under- and
overuse of anticoagulants in patients with AF, possibly
due to the multimorbidity of these patients, complicat-
ing treatment. Further qualitative research is needed to
clarify the nature of this correlation and of the barriers
GPs experience when considering anticoagulation treat-
ment. A better knowledge of these interactions could
lead to improved preventive and curative management
of the health of older patients.
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